Ernexa Therapeutics 2025 10-K: $0.0M Revenue, Net Loss $(14.08)M

Ernexa Therapeutics reported zero revenue in 2025, a significant drop from $0.582 million in 2024, resulting in a net loss of $(14.08) million, an improvement from the prior year’s $(44.539) million loss. The company focused on preclinical development, secured financing through private placements and public offerings, and reduced operating expenses to extend its financial runway. These efforts include optimizing facilities and implementing corporate governance changes like a reverse stock split.